Kura Oncology (NASDAQ:KURA) Issues Earnings Results, Beats Estimates By $0.03 EPS

Kura Oncology (NASDAQ:KURA) issued its earnings results on Tuesday. The company reported ($0.36) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.03, Fidelity Earnings reports.

Shares of NASDAQ KURA traded up $0.39 during midday trading on Friday, reaching $15.53. 128,700 shares of the company’s stock were exchanged, compared to its average volume of 264,753. Kura Oncology has a 52-week low of $11.01 and a 52-week high of $21.42. The stock has a market capitalization of $672.35 million, a PE ratio of -9.03 and a beta of 2.57. The company has a debt-to-equity ratio of 0.03, a quick ratio of 23.50 and a current ratio of 23.50. The business’s fifty day moving average price is $14.95 and its two-hundred day moving average price is $16.88.

A number of brokerages recently weighed in on KURA. JMP Securities reiterated a “market outperform” rating and issued a $22.00 target price on shares of Kura Oncology in a report on Thursday, September 5th. ValuEngine cut Kura Oncology from a “buy” rating to a “hold” rating in a report on Monday, October 21st. Deutsche Bank initiated coverage on Kura Oncology in a report on Thursday, July 18th. They issued a “buy” rating and a $28.00 target price on the stock. Zacks Investment Research cut Kura Oncology from a “hold” rating to a “sell” rating in a research note on Tuesday. Finally, BidaskClub upgraded Kura Oncology from a “strong sell” rating to a “sell” rating in a research note on Friday, October 18th. Two analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $26.22.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Further Reading: Gap Down Stocks

Earnings History for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.